Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ReutersLegal Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::334944709.png) Reuters Legal [@ReutersLegal](/creator/twitter/ReutersLegal) on x 100.1K followers
Created: 2025-07-21 17:40:16 UTC

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $XX million after finding that Revance's anti-wrinkle medication Daxxify infringed patents covering Allergan's rival drug Botox.

![](https://pbs.twimg.com/card_img/1945500487349911552/1TXO9x3X?format=jpg&name=800x419)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947350930132746366/c:line.svg)

[Post Link](https://x.com/ReutersLegal/status/1947350930132746366)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

ReutersLegal Avatar Reuters Legal @ReutersLegal on x 100.1K followers Created: 2025-07-21 17:40:16 UTC

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $XX million after finding that Revance's anti-wrinkle medication Daxxify infringed patents covering Allergan's rival drug Botox.

XXX engagements

Engagements Line Chart

Post Link

post/tweet::1947350930132746366
/post/tweet::1947350930132746366